Sutro Biopharma’s (STRO) “Sell (E+)” Rating Reiterated at Weiss Ratings

Sutro Biopharma (NASDAQ:STRO)‘s stock had its “sell (e+)” rating reissued by stock analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

STRO has been the topic of a number of other reports. Wells Fargo & Company reduced their target price on shares of Sutro Biopharma from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 12th. Wall Street Zen raised shares of Sutro Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Finally, Piper Sandler raised shares of Sutro Biopharma from a “neutral” rating to an “overweight” rating and set a $2.00 price objective on the stock in a research report on Monday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Sutro Biopharma has an average rating of “Hold” and an average target price of $4.47.

Sutro Biopharma Price Performance

NASDAQ:STRO opened at $0.85 on Wednesday. The firm’s 50-day moving average price is $0.88 and its 200-day moving average price is $0.83. The company has a market capitalization of $72.37 million, a PE ratio of -0.34 and a beta of 1.61. Sutro Biopharma has a 1-year low of $0.52 and a 1-year high of $4.60.

Sutro Biopharma (NASDAQ:STRO) last released its earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.25. The firm had revenue of $63.74 million for the quarter, compared to the consensus estimate of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. Equities analysts anticipate that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Institutional Trading of Sutro Biopharma

A number of institutional investors have recently made changes to their positions in STRO. RA Capital Management L.P. purchased a new stake in shares of Sutro Biopharma during the 1st quarter valued at about $2,885,000. Velan Capital Investment Management LP lifted its stake in shares of Sutro Biopharma by 197.1% in the 2nd quarter. Velan Capital Investment Management LP now owns 3,060,000 shares of the company’s stock worth $2,185,000 after purchasing an additional 2,030,000 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Sutro Biopharma by 78.9% in the 1st quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company’s stock worth $2,037,000 after purchasing an additional 1,382,661 shares during the period. AQR Capital Management LLC lifted its stake in shares of Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after purchasing an additional 1,206,330 shares during the period. Finally, Affinity Asset Advisors LLC bought a new position in shares of Sutro Biopharma in the 1st quarter worth approximately $490,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.